GlassScriptPhysician profile
Jared Tyler Mathews
NPI 1174017545
$5,221.79
in general payments reported to CMS, 2019-2025
25 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $1,043 · 2023: $1,397 · 2024: $1,240 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,709 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,709.33 |
| Education | $155.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $720.92 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $636.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $504.58 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $433.84 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.62 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $240.23 | 2022-2024 | Xarelto |
| Pfizer INC. | $190.80 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.63 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $147.46 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.62 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $109.88 | 2021-2023 | Belsomra, Steglatro |
| Exact Sciences Corporation | $104.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $76.74 | 2021-2022 | |
| Amgen INC. | $49.81 | 2024 | Repatha, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.22 | 2021-2023 | |
| Glaxosmithkline, LLC. | $44.45 | 2021-2022 | |
| Abbott Laboratories | $38.14 | 2024-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $36.65 | 2024 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $34.65 | 2021-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $28.59 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.05 | 2025 | Caplyta |
| Acadia Pharmaceuticals INC | $20.94 | 2025 | Daybue |
| Amneal Pharmaceuticals LLC | $15.17 | 2021 | |
| Eisai INC. | $13.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.